STAAR Surgical Company (NASDAQ:STAA)
today announced the creation of a team of leading ophthalmic surgeons, CAST
(Collamer(R) Accommodating Study Team), to work with the Company in a collaborative
effort in evaluating the accommodative properties of its Collamer lens technology.
Accommodating Intraocular Lenses (IOLs) are implantable lenses designed to restore
the eye's ability to "accommodate," or to adjust to see near and far
as does the natural eye. This ability diminishes with age, and conventional
IOLs used in cataract surgery do not restore it.
"Our patented Collamer material is similar to the eye's natural crystalline
lens in its ability to refract light, its flexibility and high water content
- all characteristics necessary for high quality visual outcomes," said
Barry G. Caldwell, President and CEO of STAAR Surgical. "During the recent
American Academy of Ophthalmic Meeting we formed CAST, which is currently comprised
of seven leading ophthalmologists, to investigate the baseline accommodative
ability of our Collamer lens. We have reviewed published clinical data by Dr.
Liz Davis and Dr. Liviu Saimovici reporting the accommodative properties of
our Collamer Single Piece Lens as well as feedback from ophthalmologists involved
in other clinical comparisons where the Three Piece Collamer lens showed accommodative
properties."
To explore the accommodative properties of Collamer a phased approach will
be used. The members of the CAST team will begin Phase One with the launch of
the Collamer Aspheric Single Piece Lens. The initial goal is to collect baseline
accommodative data on the performance of the lens. Each member will collect
near and distance visual acuity data from their patients implanted with the
Collamer lens. STAAR's research and development team has engineered changes
to the current lens to maximize the current levels of accommodation. During
Phase Two CAST will evaluate these design changes against the baseline accommodative
data collected from Phase One. The Company does not currently believe that these
changes would require supplemental premarket approval from the FDA, which means
the redesigned lens could be available during 2009. Once data is completed the
Company will decide whether to apply for an accommodative labeling claim from
the FDA. Phase Three will involve a newly designed Collamer Lens which would
require a full clinical study and submission to the FDA for approval to commercialize
the device and make accommodative claims in the U.S.
Visian ICL Highlighted on CBS produced show, "The Doctors"
STAAR also uses the Collamer material in the Visian ICL, a product that provides
an alternative to LASIK for refractive patients. Dr. Paul Dougherty, who is
a member of CAST, appeared on the November 14th airing of a nationally syndicated
show, "The Doctors." On the program Dr. Dougherty was confronted with
a patient who had worn glasses since the age of six and had been told by other
ophthalmologists that LASIK was not an option. The Visian ICL procedure was
performed and the patient was able to see 20/15 or better immediately. The patient
reported that she could see "better than ever in her entire life."
Dr. Dougherty referred to the Visian ICL procedure as providing HD Vision or
High Quality Vision. The day the segment aired the number of visitors to the
Visian ICL website increased by tenfold. The segment can be viewed by visiting:
www.visianinfo.com and clicking on media coverage.
Collamer is a proprietary collagen copolymer material developed by STAAR. Its
name derives from the material's composition; it is a 100 percent pure collagen
copolymer. Collamer is composed of a poly-HEMA based copolymer, a small amount
of collagen and a UV-absorbing chromophore (light absorbing chemical). When
fully hydrated, the Collamer lens material possesses a high water content concentrated
at the surface of the lens. The distribution of the water content (the bulk
at the lens's surface) creates an anti-reflective interface in Collamer lenses.
Other characteristics of the Collamer lens are its low levels of aberrations,
biocompatibility and bio-adhesive properties. These unique features make Collamer
an ideal optic material and highly suitable for an accommodative lens. STAAR's
formula and processes for making Collamer are protected by patents. Lenses made
of Collamer have been approved by the FDA for implantation since 2000.